Erythrocyte aggregation and leukocyte isolation

US11821891B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11821891-B2
Application numberUS-202017113527-A
CountryUS
Kind codeB2
Filing dateDec 7, 2020
Priority dateDec 1, 2015
Publication dateNov 21, 2023
Grant dateNov 21, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A device and/or methodology are described that include a mechanism for separating erythrocytes from other constituents of blood and for purifying leukocytes from blood. The separation and purification aspects may be provided in separate components or within the same component. The separation aspect assists in separating erythrocytes (red blood cells) from other cells in blood, such as by aggregation of the red blood cells. A suitable aggregation device or device component uses chambers with at least one small dimension (e.g., a microfluidic chip) to control the interaction of the blood with a solution containing a high molecular weight polymer (e.g., dextran) to achieve separation.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method, comprising: loading a blood sample into a loading well on a first surface of a microfluidic device, wherein the loading well comprises a loading well outlet; directing the blood sample from the loading well outlet into a vertical aggregation channel, via a vertical aggregation channel inlet coupled to the loading well outlet, wherein the vertical aggregation channel comprises a solution of high-molecular weight polysaccharide is present, wherein the blood sample has higher density than the solution, and wherein dimensions of the vertical aggregation channel enable stabilization of the higher density blood sample above the lower-density solution despite being energetically unstable, and wherein the vertical aggregation channel inlet is coupled to the loading well outlet at first longitudinal position along a longitudinal axis; directing the blood sample along the longitudinal axis in a direction perpendicular to a horizontal interface formed between the solution and the blood sample; aggregating red blood cells present in the blood sample at the horizontal interface formed between the solution and the blood sample, wherein the aggregated red blood cells sediment into the solution and out of the blood sample leaving a red blood cell separated sample; and directing the aggregated red blood cells from a vertical aggregation channel outlet of the vertical aggregation channel to an output channel via an output channel inlet that is coupled to the vertical aggregation channel outlet at a second longitudinal position along the longitudinal axis, wherein the second longitudinal position is downstream of the first longitudinal position relative to the longitudinal axis. 2. The method of claim 1 , wherein the high-molecular weight polysaccharide comprises dextran. 3. The method of claim 1 , wherein the blood sample and solution are not mixed as part of the red blood cell aggregation step. 4. The method of claim 1 , wherein the vertical aggregation channel is sized so as to cause surface tension sufficient to maintain the higher-density blood layer over the lower-density solution. 5. The method of claim 1 , further comprising: flowing at least a red blood cell depleted portion of the red blood cell separated sample over an affinity surface configured to bind one or more blood components. 6. The method of claim 5 , wherein the one or more blood components comprise one or more types of white blood cells. 7. The method of claim 5 , wherein the one or more blood components comprise one or more of plasma proteins, lipids, circulating nucleic acids, circulating tumor cells, viruses, or bacteria. 8. The method of claim 1 , wherein the blood sample is less than or equal to 100 μl whole blood. 9. The method of claim 1 , wherein an inner diameter the vertical aggregation channel tapers towards the second longitudinal position wherein each diameter of the output channel is substantially perpendicular to the longitudinal axis, wherein at least one diameter of the output channel is less than or equal to 450 μm. 10. The method of claim 1 , wherein the vertical aggregation channel in at least one dimension is less than or equal to 225 μm. 11. The method of claim 1 wherein the solution comprises a 1%-10% dextran concentration at a molecular weight of 100-1,500 kDa. 12. The method of claim 1 , comprising directing one or more reagents from one or more reagent wells to the loading well, wherein the one or more reagent wells are disposed adjacent to the loading well, and wherein the one or more reagent wells are fluidly coupled to a capture channel and configured to hold reagents for treating or analyzing cells captured by the capture channel. 13. The method of claim 1 , comprising directing the aggregated red blood cells from an output channel outlet of the output channel into a capture channel via a capture channel inlet that is coupled to the output channel outlet of the output channel at a third longitudinal position along the longitudinal axis, wherein the third longitudinal position is downstream of the second longitudinal position relative to the longitudinal axis, and the capture channel comprising an antibody coated surface configured to selectively bind at least one type of blood cell in the aggregated red blood cells, wherein the capture channel is downstream of the vertical aggregation channel.

Assignees

Inventors

Classifications

  • Partitioning blood components · CPC title

  • characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces · CPC title

  • characterised by integrated valves (throttle valves in microfluidic sample containers B01L3/502746) · CPC title

  • specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules · CPC title

  • characterised by multiphase flow arrangements · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11821891B2 cover?
A device and/or methodology are described that include a mechanism for separating erythrocytes from other constituents of blood and for purifying leukocytes from blood. The separation and purification aspects may be provided in separate components or within the same component. The separation aspect assists in separating erythrocytes (red blood cells) from other cells in blood, such as by aggreg…
Who is the assignee on this patent?
Gen Electric
What technology area does this patent fall under?
Primary CPC classification G01N33/5002. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).